Innate Pharma
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Innate Pharma sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).
Innate Pharma: 12 sponsored US clinical trials, 3 recruiting.
Innate Pharma sponsors 12 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mycosis Fungoides/Sezary Syndrome, with 1 trials.
Top-decile sponsor footprint
Innate Pharma ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
12 total, page 1 of 1
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
NCT06781983
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
NCT06088654
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
NCT05742607
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
NCT03902184
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
NCT05321147
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
NCT03665129
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT02643550
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
NCT02557516
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
NCT02593045
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
NCT01222286
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
NCT01217203
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
NCT00552396
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 3 |
What is open in the Innate Pharma pipeline
3 recruiting of 12 indexed (25% open); 6 completed (50%).
Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Mycosis Fungoides/Sezary Syndrome (1 trial), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Innate Pharma: open-pipeline peers nationwide
Peers matched on 12 registered trials and 25% open enrollment, not the therapeutic-area sidebar.
Innate Pharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 12 trials (± recruiting share)
- Alachua Government Services · 12 trials · 0% recruiting
- Allergy Therapeutics · 12 trials · 0% recruiting
- Ampio Pharmaceuticals. · 12 trials · 0% recruiting
- Angiodynamics · 12 trials · 17% recruiting
Sponsors near 25% open enrollment (± trial volume)
- AB Science · 25% recruiting · 8 trials
- Abbott Point of Care · 25% recruiting · 8 trials
- Abdul Latif Jameel Poverty Action Lab · 25% recruiting · 4 trials
- Accutar Biotechnology · 25% recruiting · 4 trials
Related
What to do with this Innate Pharma page
12 registered trials is a research-attention snapshot, not an endorsement of Innate Pharma or any single study.
- 3 of Innate Pharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Mycosis Fungoides/Sezary Syndrome is the condition Innate Pharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Mycosis Fungoides/Sezary Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Innate Pharma pipeline card: 12 registered trials from official public datasets.Report a data error.